General Information of Drug (ID: DMI6TKU)

Drug Name
PROTOSTEMODIOL Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
24769900
TTD Drug ID
DMI6TKU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [2]
Cotinine DMCEZ1B Insecticide N.A. Approved [3]
Pancuronium DMB0VY8 Anaesthesia 9A78.6 Approved [4]
Atracurium DM42HXN Anaesthesia 9A78.6 Approved [4]
Mecamylamine DMGQFYB Essential hypertension BA00 Approved [5]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [6]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [7]
BMS-954561 DM7XV4R Diabetic neuropathy 8C0Z Phase 2 [8]
ASM-024 DM35S2I Asthma CA23 Phase 2 [9]
NIC-002 DMKLJMI Nicotine dependence 6C4A.2 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nicotinic acetylcholine receptor (nAChR) TTJSZTB NOUNIPROTAC Inhibitor [1]

References

1 Alkaloids from stems and leaves of Stemona japonica and their insecticidal activities. J Nat Prod. 2008 Jan;71(1):112-6.
2 Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
3 Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
4 Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
5 Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
8 EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
9 Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
10 Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.